Products
Zaltenibart Biosimilar Monoclonal Antibody (MASP-3) for Research
Cat No.: GMP-Bios-INN-1470
Anti-MASP3 therapeutic antibody (Pre-made Zaltenibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Zaltenibart (development code OMS-906) is a humanized monoclonal antibody targeting MASP3. It is developed by Helion Biotech and Medical Research Council and University of Leicester and Omeros Corporation for Glomerulonephritis, Paroxysmal nocturnal haemoglobinuria in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1470-1mg | 1mg | 3090 |
| GMP-Bios-INN-1470-10mg | 10mg | |
| GMP-Bios-INN-1470-100mg | 100mg | |
| GMP-Bios-INN-1470-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Zaltenibart biosimilar, Whole mAb, Anti-MASP3 Antibody: Anti-MASP1/Mannan-binding lectin serine protease 1/Complement factor MASP-3/Complement-activating component of Ra-reactive factor therapeutic antibody |
| INN Name | Zaltenibart |
| Target | MASP3 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Helion Biotech;Medical Research Council;University of Leicester;Omeros Corporation |
| Conditions Approved | na |
| Conditions Active | Glomerulonephritis;Paroxysmal nocturnal haemoglobinuria |
| Conditions Discontinued | Arthritis |
| Production | na |
| Development Tech | na |
